Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Dr. Ahn on Limitations of Targeted Therapy in CRC

July 24th 2020

Daniel H. Ahn, DO, an oncologist, internist, and assistant professor of medicine at Mayo Clinic, discusses current limitations of targeted therapy in the colorectal cancer.

Dr. Lenz on Choosing Between Regorafenib and TAS-102 in CRC

July 23rd 2020

Heinz-Josef Lenz, MD, FACP, discusses factors to consider when choosing between regorafenib and trifluridine/tipiracil in the third-line treatment of patients with colorectal cancer.

Dr. Ahn on the KEYNOTE-177 Trial in Newly Diagnosed MSI-H/dMMR mCRC

July 23rd 2020

Daniel H. Ahn, DO, discusses updated findings from the phase 3 KEYNOTE-177 trial in patients with newly diagnosed microsatellite instability–high/mismatch repair deficient metastatic colorectal cancer.

Dr. Ahn on Advancing Actionable Alterations in CRC

July 17th 2020

Daniel H. Ahn, DO, discusses advancing actionable alterations in colorectal cancer.

Ahn Expands on Advances Made With Actionable Alterations in CRC

July 17th 2020

Daniel H. Ahn, DO, discusses the slew of actionable alterations that have emerged in colorectal cancer in recent years, including targeted therapies that are boosting survival outcomes.

Dr. Bach on Examining ctDNA in CRC

July 16th 2020

Sander Bach, MD, PhD, discusses research examining circulating tumor DNA in colorectal cancer.

Three Key ASCO Studies Showcase Targeted Advances

July 15th 2020

Molecularly targeted therapies showed practice-changing results for patients with biomarker-driven lung, colorectal, and ovarian cancers in phase 3 randomized clinical trial findings.

Dr. Bach Discusses Ongoing Research With ctDNA in CRC

July 15th 2020

Sander Bach, MD, PhD, discusses ongoing research with circulating tumor DNA in colorectal cancer.

Dr. Bach on the Results of a Systematic Review of ctDNA in CRC

July 14th 2020

Sander Bach, MD, PhD, discusses the results of a systematic review of circulating tumor DNA in colorectal cancer.

Dr. Ahn on Left- Versus Right-Sided Tumors in CRC

July 13th 2020

Daniel H. Ahn, DO, discusses left- versus right-sided tumors in colorectal cancer.

Dr. Kopetz on the Rationale for the BEACON CRC Study in BRAF V600E-Mutant mCRC

July 8th 2020

Scott Kopetz, MD, PhD, FACP, discusses the rationale for the phase 3 BEACON CRC trial in BRAF V600E-mutant metastatic colorectal cancer.

Dr. Siena on the Design of the DESTINY-CRC01 Trial in HER2+ Metastatic CRC

July 7th 2020

Salvatore Siena, MD, provides an overview of the DESTINY-CRC01 trial in DESTINY-CRC01 trial in HER2-positive metastatic colorectal cancer.

Dr. Bach on the Rationale to Conduct a Systematic Review of ctDNA in CRC

July 6th 2020

Sander Bach, MD, PhD, discusses the rationale to conduct a systematic review of circulating tumor DNA in colorectal cancer.

Dr. Kim on Efficacy and Next Steps With Regorafenib/Nivolumab Combo in CRC

July 3rd 2020

Richard D. Kim, MD, discusses the efficacy of and next steps for a phase 1/1b study with regorafenib and nivolumab in patients with mismatch repair proficient advanced refractory colorectal cancer.

Dr. Lenz on Updated Data From CheckMate 142 With Nivolumab + Ipilimumab in mCRC

July 2nd 2020

Heinz-Josef Lenz, MD, FACP, discusses updated efficacy data from the phase 2 CheckMate-142 trial with nivolumab plus low-dose ipilimumab in metastatic colorectal cancer.

Dr. Fakih on the Safety Profile of AMG 510 in KRAS G12C-Mutated CRC

July 2nd 2020

Marwan Fakih, MD, discusses the safety profile of AMG 510 in KRAS G12C-mutated colorectal cancer.

Research Reflections: Weinberg Weighs in on Thought-Provoking Data in CRC

June 29th 2020

Benjamin Weinberg, MD, shares the clinical implications of how data from the 2020 ASCO Virtual Scientific Program may impact in the treatment of patients with colorectal cancer and projects what the future may hold in the space.

FDA Approves First-Line Pembrolizumab for MSI-H/dMMR Metastatic Colorectal Cancer

June 29th 2020

The FDA has approved pembrolizumab (Keytruda) for the first-line treatment of patients with unresectable or metastatic microsatellite instability–high or mismatch repair deficient colorectal cancer.

Future Directions in Later Line Therapy for mCRC

June 29th 2020

Key Trials in mCRC: I/O Combination Therapies

June 29th 2020